Free Trial

7 Undervalued Growth Stocks Ready for Reversal - 4 of 7

 
 

#4 - Medtronic (NYSE:MDT)

Healthcare is another sector for growth-oriented investors to watch. Medtronic PLC (NYSE: MDT) is the only pure-play medical device company with a product portfolio filled with life-saving devices such as implantable defibrillators, glucose monitoring systems, and surgical tools.  In fact, it has 50% market share in its core heart devices. 

The company beat on its top and bottom lines when it reported earnings, and both numbers were higher year-over-year despite tougher comparisons. It also raised its full-year guidance, and investors get a dividend that has a yield of 3.13%. 

That doesn’t seem to excite analysts much. They have a consensus Hold on MDT stock with a price target that suggests future earnings growth is priced into the stock.  

In fairness, it is trading near the top of its 52-week range. However, the stock trades at a forward P/E of around 16x earnings, That’s significantly lower than the sector average. And the company should get a tailwind from an aging population combined with the growing demand for acute care.  

 

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. Read More 
Current Price
$90.07
Consensus Rating
Hold
Ratings Breakdown
7 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$95.36 (5.9% Upside)

 

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.